Although BCL-2:MCL-1 ratio was a reasonably good predictor of sensitivity in our limited pool of lymphoma cells, consistent with some studies [47], [48], microplate-based respirometry also predicted ABT-737 sensitivity, as well as sensitivity to the oral form ABT-263 (Navitoclax) that is the subject of multiple clinical trials. Here, MCL1 is linked to lymphoma.